Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Optimi Health Corp (OP:OPTHF)

0.1405 +0.0033 (+2.41%)
Streaming Delayed Price Updated: 12:49 PM EDT, Aug 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Optimi Health Corp

< Previous 1 2 Next >
Psychedelic Biotech Psyence Grows Pipeline With Trials And Psilocybin Drug Developer Acquisition
Psyence Biomed launches Phase IIb trials for psilocybin in palliative care and Alcohol Use Disorder, bolstering its clinical pipeline with key acquisitions and partnerships. 
Via Benzinga
New Milestone In Psychedelics Market: Canadian Start-Up Will Export Psilocybin And MDMA To Australia
Canada Magic Mushrooms and MDMA market is hitting new milestones as canada has licensed Optimi to export psilocybin and MDMA to Australia 
Via Benzinga
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
 
Via Benzinga
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
 
Via Benzinga
Optimi To Supply Psilocybin For New Zealand's Mātai Medical Research Institute
 
Via Benzinga
Two Top Biotechs Forge MDMA Supply Deals For Clinical Research
 
Via Benzinga
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
 
Via Benzinga
Psychedelics Headlines: Predicting Readiness, Correcting The Hype, Good And Bad Drugs, Training Programs And More
 
Via Benzinga
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available. 
Via Benzinga
Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA's Stance, The Therapist's Role & More
Welcome to Benzinga's weekly psychedelics news roundup. We have pulled together several must-read news items from the last week of December 2023 and the first of January 2024.  
Via Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification 
Via Benzinga
Topics Artificial Intelligence
Optimi Health Will Supply Psychedelics To Canada's SAP, Secures CA$1M Private Financing
Health Canada has approved an amendment to Optimi Health’s (OTCQX: OPTHF) dealer's license, effectively allowing the company to supply MDMA and psilocybin drugs to the country’s Special Access Program... 
Via Benzinga
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published 
Via Benzinga
Natural Psilocybin Companies Diversify: Latest By Optimi, Red Light Holland And A European Player
Optimi Completes Novel Extraction Process and Files U.S. Prov. Patent 
Via Benzinga
MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University
Numinus Wellness (OTCMKTS: NUMIF) with support from the Multidisciplinary Association for Psychedelic Studies (MAPS) will utilize Optimi Health’s (OTCMKTS: OPTHF) Good Manufacturing Practice... 
Via Benzinga
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application... 
Via Benzinga
The Psychedelic Mushrooms Market; Between Legitimate Harvesting And Illegal Retail Sales
While psychedelics reform is clearly gaining momentum, not only in the U.S. but notably in places like Australia and less so Canada. The fact is, all compounds remain currently Schedule I drugs (or... 
Via Benzinga
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths... 
Via Benzinga
Optimi Health Boosts Psilocybin Production With New Health Canada License And Supply Deal
Psychedelics research and manufacturing company Optimi Health Corp. (OTCQX: OPTHF) received a “Natural Health Product Site" license, adding to its existing permits to produce and supply psychedelic... 
Via Benzinga
What To Expect From The Benzinga Psychedelics Capital Conference, The Must-Attend Event For This Emerging Industry
The world of psychedelics is evolving rapidly, and the Benzinga Psychedelics Capital Conference is the premier event for those who want to be part of this exciting journey. 
Via Benzinga
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been... 
Via Benzinga
Australia Receives First Batch Of Clinical-Grade Psilocybin From Mindset Pharma And PharmAla
The exclusive sales partnership between psychedelics biotechs Mindset Pharma (OTCQB: MSSTF) and PharmAla Holdings resulted in the first sale of Mindset’s GMP-compliant psilocybin in Australia. 
Via Benzinga
Latest Psychedelics Deals: Optimi Supplies Australia, Awakn Partners Licensing In California
Optimi Health Enters Australian Medical Psychedelics Market Via Mind Medicine Australia 
Via Benzinga
Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More
Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More 
Via Benzinga
How Do Psilocybin And MDMA Work Together? This Proposed Experiential Study Is Set To Find Out
Licensed psychedelic drugs producer Optimi Health Corp. (OTCQX: OPTHF) submitted a Health Canada clinical trial application (CTA) for a Phase 1 study that will assess the safety of combining its... 
Via Benzinga
MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations
Considering MDMA will likely be the first psychedelic to receive FDA approval for psychotherapeutic use to treat serious mental health conditions such as PTSD, seve 
Via Benzinga
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First? 
Via Benzinga
Here Are The Latest Psychedelics Partnerships From Production & Supply Chain To Community Action
Let’s do a quick tour of some of the latest announcements made by psychedelics companies over the past week. We promise you’ll be informed in less time than it takes to brew your coffee. New,... 
Via Benzinga
Canada Update: Psychedelics Legal Landscape, Overview & Near-Term Predictions
Canada is hosting discussions on legal access to psychedelic-assisted therapies, especially after Alberta passed regulatory measures for this type of health s 
Via Benzinga
Optimi Health Announces C$3.27 Million Private Placement with Strategic Investment from Lululemon Founder Chip Wilson
Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP-grade psilocybin, synthetic psychedelic substances and... 
Via PressReach
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.